$8.07
1.47% day before yesterday
Nasdaq, Dec 26, 10:00 pm CET
ISIN
US03476J1079
Symbol
ELTX

Angion Biomedica Corp Stock price

$8.07
-1.09 11.90% 1M
+0.17 2.15% 6M
+2.97 58.24% YTD
+3.00 59.17% 1Y
-8.03 49.88% 3Y
-162.13 95.26% 5Y
-162.13 95.26% 10Y
-162.13 95.26% 20Y
Nasdaq, Closing price Fri, Dec 26 2025
-0.12 1.47%
ISIN
US03476J1079
Symbol
ELTX
Industry

Key metrics

Basic
Market capitalization
$141.1m
Enterprise Value
$130.3m
Net debt
positive
Cash
$20.6m
Shares outstanding
17.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
37.0
Financial Health
Equity Ratio
-40.1%
Return on Equity
459.7%
ROCE
-194.6%
ROIC
-576.2%
Debt/Equity
2.5
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-42.8m | -
EBIT
$-42.3m | $-37.6m
Net Income
$-45.9m | $-44.1m
Free Cash Flow
$-38.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-7.5% | -
EBIT
-4.0% | 16.6%
Net Income
2.5% | 15.2%
Free Cash Flow
-1.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.7
FCF per Share
$-2.3
Short interest
10.0%
Employees
32
Rev per Employee
$0.0
Show more

Is Angion Biomedica Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Angion Biomedica Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Angion Biomedica Corp forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Angion Biomedica Corp forecast:

Buy
88%
Hold
13%

Financial data from Angion Biomedica Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
0% 0%
-
- Research and Development Expense 31 31
5% 5%
-
-43 -43
7% 7%
-
- Depreciation and Amortization -0.40 -0.40
142% 142%
-
EBIT (Operating Income) EBIT -42 -42
4% 4%
-
Net Profit -46 -46
2% 2%
-

In millions USD.

Don't miss a Thing! We will send you all news about Angion Biomedica Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Angion Biomedica Corp Stock News

Neutral
GlobeNewsWire
11 days ago
BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on December 15, 2025, Elicio granted an aggregate of 157,193 inducement stock options to three new employees, as an inducement material to each indivi...
Neutral
GlobeNewsWire
16 days ago
Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized tumor neoantigens not present in the targeted immunotherapy 87% (13/15) of evaluated patients demonstrated induction of T cell responses to tumor neoantigens beyond mKRAS following ELI-002 7P therapy The induction of non-mKRAS antigen-specific T cell re...
Neutral
GlobeNewsWire
about one month ago
BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Marc J. Wolfgang, M.S.
More Angion Biomedica Corp News

Company Profile

Angion Biomedica Corp. operates as a biopharmaceutical company. It focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 06, 1998 and is headquartered in Uniondale, NY.

Head office United States
CEO Robert Connelly
Employees 32
Founded 2011
Website elicio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today